Efficacy of Vismodegib

Vismodegib (Vismodegib) is a cancer drug containing the active substance vismodegib. It is used to treat adults with advanced basal cell carcinoma, a slow-growing skin cancer. When the cancer is metastatic (has spread to other parts of the body) and is causing symptoms, or when it is locally advanced (has begun to spread to nearby areas) and is not suitable for surgery or radiation therapy (with radiation therapy), it can be treated with Vimodegib under the guidance of a doctor.

Vimodegib was studied in a major study involving 104 patients with metastatic or locally advanced basal cell carcinoma. These patients were given vismodegib until their disease worsened or they could no longer tolerate the treatment or withdrew from the study. Vimodegib was not compared with any other treatment. The primary measure of effectiveness is response to treatment, based on at least a 30% reduction in tumor size or the disappearance of all signs of cancer (objective response rate). About 33% of patients with metastatic disease and 48% of patients with locally advanced disease responded to treatment. Premature epiphyseal fusion has been reported in pediatric patients treated with vismodegib and its use may not be recommended in children.

The original drug of Vimodegib is not currently on the market in the country, so it cannot be included in medical insurance. Overseas, Vimodegiboriginal drug has Turkish version and European version, specificationsThe price of 150mg*28 capsules per box may be around RMB 10,000-30,000 (the price may fluctuate due to the exchange rate). The price is very expensive, and there are currently no generic versions of Vimodegib. For more drug information and specific prices, please consult Yaodei Medical Consultants.